Ligand Pharmaceuticals (LGND) Enterprise Value (2010 - 2026)

Ligand Pharmaceuticals has disclosed Enterprise Value across 17 years of filings, most recently posting -$779.4 million for Q1 2026.

• Enterprise Value for Q1 2026 came in at -$779.4 million, down 273.1% year-over-year; the trailing twelve-month figure through Mar 2026 was -$779.4 million (down 273.1% YoY), and the FY2025 annual result was -$190.6 million, up 25.61% from the prior year.
• Enterprise Value came in at -$779.4 million for Q1 2026 at Ligand Pharmaceuticals, down from -$190.6 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$74.8 million in Q3 2024 to a low of -$779.4 million in Q1 2026.
• The 5-year median for Enterprise Value is -$211.9 million (2022), against an average of -$265.0 million.
• Across the five-year window, Enterprise Value jumped 62.44% in 2022 and sank 788.97% in 2025, its largest moves.
• Ligand Pharmaceuticals' Enterprise Value stood at -$211.9 million in 2022, then grew by 19.62% to -$170.3 million in 2023, then slumped by 50.41% to -$256.2 million in 2024, then climbed by 25.61% to -$190.6 million in 2025, then plunged by 309.01% to -$779.4 million in 2026.
• The last three Enterprise Value figures came in at -$779.4 million (Q1 2026), -$190.6 million (Q4 2025), and -$664.5 million (Q3 2025), per Business Quant data.